Potential of AKT2 expression as a predictor of lymph-node metastasis in invasive breast carcinoma of no special type
- PMID: 34111909
- PMCID: PMC8353139
- DOI: 10.4132/jptm.2021.04.26
Potential of AKT2 expression as a predictor of lymph-node metastasis in invasive breast carcinoma of no special type
Abstract
Background: Invasive breast carcinoma of no special type (IBC-NST) is the most common type of breast cancer and mainly causes regional lymph-node metastasis (LNM). We investigated the potential for AKT2 expression as a predictive biomarker for LNM in IBC-NST.
Methods: Forty-eight paraffin blocks containing IBC-NST primary tumors were divided into two groups based on presence or absence of LNM. Age, tumor grade, tumor size, lymphovascular invasion (LVI), and AKT expression were assessed. AKT2 expression was assessed based on immunohistochemical staining, while other data were collected from archives.
Results: Multiple logistic regression results showed that AKT2 expression and LVI were significantly associated with LNM (odds ratio [OR], 5.32; 95% confidence interval [CI], 1.42 to 19.93 and OR, 4.46; 95% CI, 1.17 to 16.97, respectively). AKT2 expression was able to discriminate against LNM (area under the receiver operating characteristic, 0.799 ± 0.063; 95% CI, 0.676 to 0.921) at an H-score cutoff of 104.62 (83.3% sensitivity, 62.5% specificity).
Conclusions: AKT2 expression has potential as a predictor of LNM in IBC-NST. The H-score cutoff for AKT2 expression can be used as a classification guide in future studies.
Keywords: AKT2; Breast neoplasms; Immunohistochemistry; Metastasis.
Conflict of interest statement
The authors declare that they have no potential conflicts of interest.
Figures



Similar articles
-
Exploring the Integrated Role of AKT2, CD44v6, And MT1-MMP as Predictors of Axillary Lymph Node Metastasis in Invasive Breast Carcinoma of No Special Type.Iran J Pathol. 2022 Fall;17(4):480-490. doi: 10.30699/IJP.2022.551244.2866. Epub 2022 Oct 5. Iran J Pathol. 2022. PMID: 36532641 Free PMC article.
-
CD44 Variant Exon 6 Isoform Expression as a Potential Predictor of Lymph Node Metastasis in Invasive Breast Carcinoma of No Special Type.Int J Breast Cancer. 2021 Dec 10;2021:1586367. doi: 10.1155/2021/1586367. eCollection 2021. Int J Breast Cancer. 2021. PMID: 34925920 Free PMC article.
-
Risk factors of lymph node metastasis or lymphovascular invasion for early gastric cancer: a practical and effective predictive model based on international multicenter data.BMC Cancer. 2019 Nov 6;19(1):1048. doi: 10.1186/s12885-019-6147-6. BMC Cancer. 2019. PMID: 31694573 Free PMC article.
-
Relationship of lymphovascular invasion with lymph node metastasis and prognosis in superficial esophageal carcinoma: systematic review and meta-analysis.BMC Cancer. 2020 Mar 4;20(1):176. doi: 10.1186/s12885-020-6656-3. BMC Cancer. 2020. PMID: 32131772 Free PMC article.
-
Risk factors for lymph node metastasis in T1 esophageal squamous cell carcinoma: A systematic review and meta-analysis.World J Gastroenterol. 2021 Feb 28;27(8):737-750. doi: 10.3748/wjg.v27.i8.737. World J Gastroenterol. 2021. PMID: 33716451 Free PMC article.
Cited by
-
The potential of lunasin extract for the prevention of breast cancer progression by upregulating E-Cadherin and inhibiting ICAM-1.F1000Res. 2021 Sep 8;10:902. doi: 10.12688/f1000research.55385.1. eCollection 2021. F1000Res. 2021. PMID: 34691393 Free PMC article.
-
Exploring the Integrated Role of AKT2, CD44v6, And MT1-MMP as Predictors of Axillary Lymph Node Metastasis in Invasive Breast Carcinoma of No Special Type.Iran J Pathol. 2022 Fall;17(4):480-490. doi: 10.30699/IJP.2022.551244.2866. Epub 2022 Oct 5. Iran J Pathol. 2022. PMID: 36532641 Free PMC article.
-
CD44 Variant Exon 6 Isoform Expression as a Potential Predictor of Lymph Node Metastasis in Invasive Breast Carcinoma of No Special Type.Int J Breast Cancer. 2021 Dec 10;2021:1586367. doi: 10.1155/2021/1586367. eCollection 2021. Int J Breast Cancer. 2021. PMID: 34925920 Free PMC article.
-
Correlation of Before and After Invasive Breast Cancer Neoadjuvant Chemotherapy for NFkB, Cyclin D1, and Survivin Expression.Iran J Pathol. 2023 Spring;18(2):147-155. doi: 10.30699/ijp.2023.562935.2983. Epub 2023 Jun 20. Iran J Pathol. 2023. PMID: 37600572 Free PMC article.
-
The Potential of Expression of Cyclin-D1 on Neoadjuvant Chemotherapy in Invasive Breast Carcinoma.Asian Pac J Cancer Prev. 2023 Apr 1;24(4):1131-1136. doi: 10.31557/APJCP.2023.24.4.1131. Asian Pac J Cancer Prev. 2023. PMID: 37116133 Free PMC article.
References
-
- Bray F, Ferlay J, Soerjomataram IS, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. - PubMed
-
- Song M, Bode AM, Dong Z, Lee MH. AKT as a therapeutic target for cancer. Cancer Res. 2019;79:1019–31. - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous